Prothena said it is developing therapies for diseases linked to protein dysregulation, with focus areas including Parkinson’s disease, Alzheimer’s disease and transthyretin amyloidosis. The company highlighted partnered late-stage programs including prasinezumab in a Phase 3 Parkinson’s trial (PARAISO, NCT07174310) and coramitug in a Phase 3 ATTR cardiomyopathy trial (CLEOPATTRA, NCT07207811). Prothena also cited a partnered Phase 2 Alzheimer’s program, BMS-986446, with the TargetTau-1 study (NCT06268886). Prothena reported cash, cash equivalents and restricted cash of USD 308.4 million as of December 31, 2025, and outlined a share repurchase plan of up to USD 100 million for 2026. It also said it expects up to USD 105 million in clinical milestones by year-end 2026, including USD 50 million tied to coramitug Phase 3 enrollment and a potential USD 55 million milestone related to PRX019.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prothena Corporation plc published the original content used to generate this news brief on March 09, 2026, and is solely responsible for the information contained therein.